PTJ
CRL icon

Paul Tudor Jones’s Charles River Laboratories CRL Stock Holding History

Paul Tudor Jones’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,782
Closed -$887K – 3725
2025
Q4 		$954K Sell
4,782
-87,935
-95% -$16M ﹤0.01% 2310
2025
Q3 		$14.5M Sell
92,717
-77,077
-45% -$12.2M 0.03% 586
2025
Q2 		$25.8M Buy
169,794
+100,669
+146% +$13.4M 0.06% 268
2025
Q1 		$10.4M Buy
69,125
+12,839
+23% +$2.15M 0.03% 442
2024
Q4 		$10.4M Buy
+56,286
New +$10.8M 0.04% 344
2024
Q3 		– Sell
-18,998
Closed -$3.95M – 2764
2024
Q2 		$3.92M Sell
18,998
-1,697
-8% -$385K 0.02% 752
2024
Q1 		$5.61M Sell
20,695
-45,222
-69% -$10.8M 0.04% 569
2023
Q4 		$15.6M Buy
65,917
+8,744
+15% +$1.72M 0.13% 183
2023
Q3 		$11.2M Buy
+57,173
New +$11.7M 0.11% 191
2022
Q3 		– Sell
-16,193
Closed -$3.5M – 2363
2022
Q2 		$3.46M Buy
16,193
+3,727
+30% +$911K 0.09% 282
2022
Q1 		$3.54M Buy
12,466
+1,075
+9% +$331K 0.08% 308
2021
Q4 		$4.29M Buy
+11,391
New +$4.43M 0.07% 314
2021
Q3 		– Sell
-3,368
Closed -$1.25M – 2504
2021
Q2 		$1.25M Sell
3,368
-10,418
-76% -$3.48M 0.02% 764
2021
Q1 		$4M Buy
13,786
+4,934
+56% +$1.37M 0.08% 244
2020
Q4 		$2.21M Buy
+8,852
New +$2.11M 0.06% 388
2020
Q2 		– Sell
-3,572
Closed -$451K – 1204
2020
Q1 		$451K Buy
3,572
+1,045
+41% +$157K 0.04% 533
2019
Q4 		$386K Sell
2,527
-2,663
-51% -$369K 0.02% 796
2019
Q3 		$687K Buy
+5,190
New +$696K 0.02% 616
2017
Q3 		– Sell
-6,310
Closed -$638K – 1115
2017
Q2 		$638K Sell
6,310
-4,914
-44% -$452K 0.02% 487
2017
Q1 		$1.01M Buy
11,224
+2,704
+32% +$230K 0.03% 380
2016
Q4 		$649K Sell
8,520
-380
-4% -$28.9K 0.02% 573
2016
Q3 		$742K Sell
8,900
-153,937
-95% -$12.9M 0.02% 539
2016
Q2 		$13.4M Sell
162,837
-101,722
-38% -$8.38M 0.28% 43
2016
Q1 		$20.1M Buy
264,559
+244,223
+1,201% +$18.1M 0.51% 34
2015
Q4 		$1.64M Buy
20,336
+4,267
+27% +$308K 0.05% 259
2015
Q3 		$1.02M Buy
16,069
+7,215
+81% +$518K 0.03% 381
2015
Q2 		$623K Sell
8,854
-1,268
-13% -$93.8K 0.02% 649
2015
Q1 		$803K Buy
10,122
+1,422
+16% +$105K 0.03% 473
2014
Q4 		$554K Sell
8,700
-3,100
-26% -$194K 0.02% 670
2014
Q3 		$705K Sell
11,800
-6,294
-35% -$360K 0.03% 461
2014
Q2 		$968K Buy
18,094
+1,333
+8% +$73.1K 0.04% 216
2014
Q1 		$1.01M Buy
16,761
+7,461
+80% +$435K 0.04% 192
2013
Q4 		$493K Buy
9,300
+600
+7% +$30.1K 0.02% 567
2013
Q3 		$402K Sell
8,700
-900
-9% -$41.3K 0.02% 449
2013
Q2 		$394K Buy
+9,600
New +$411K 0.03% 439

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Paul Tudor Jones's CRL Position: Q1 2026 in Review

Paul Tudor Jones sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 4,782 shares — an estimated $887K sold.

Paul Tudor Jones first reported a position in CRL in Q2 2013 and held it in 35 quarters. The position peaked at $25.8M in Q2 2025. 559 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Paul Tudor Jones reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 4,782 Charles River Laboratories shares in Q1 2026, an estimated $887K.
  • Paul Tudor Jones first reported a position in Charles River Laboratories in Q2 2013 and held it in 35 quarters.
  • Paul Tudor Jones's Charles River Laboratories position peaked at $25.8M in Q2 2025.
  • 559 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.